Drug intelligence / Profile preview

META060

Development stage
Preclinical
Lead developer
Metagenics
Modality
Small Molecules, Peptides
Administration
Oral
01

Overview

META060 is a proprietary and patented formulation of tetrahydro iso-alpha acids derived from *Humulus lupulus* L. (hops). It is being developed primarily for weight management and metabolic disorders such as obesity and insulin resistance. Preclinical studies in high-fat diet-fed mice have shown that supplementation with META060 reduces body weight gain, improves glucose tolerance, increases metabolic flexibility, and normalizes insulin sensitivity markers. The compound also demonstrates anti-inflammatory effects by inhibiting monocyte-endothelial cell interactions, suppressing multiple biomarkers of inflammation (including IL-1β, MCP-1, RANTES), reducing MMP-9 expression/activity, and inhibiting the activation of transcription factors NF-κB and AP-1. Additionally, META060 inhibits several kinases associated with inflammatory diseases (Syk, Btk, PI 3-kinase, GSK3) and osteoclastogenesis *in vitro*. These properties suggest potential therapeutic value for managing obesity-related metabolic dysfunctions as well as inflammatory conditions such as atherosclerosis or rheumatoid arthritis[1][2][4][5][6].

Other names
tetrahydro iso-alpha acids from hopsmodified hop extract
02

Targets

FOS (Activator Protein 1)BTK (Bruton tyrosine kinase)GSK3 (Glycogen synthase kinase 3 beta)NF-κBPI3K (Phosphoinositide-3-kinase regulatory subunit 6)SYK (Spleen Tyrosine Kinase)

Beyond the preview

Go deeper on META060.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on META060.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call